Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
An FDA advisory committee is scheduled to vote Wednesday on whether to approve Novo's semaglutide, which, if approved, could steal market share from Eli Lilly's Trulicity.